SAN DIEGO, July 22, 2020 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, announced today
that the company will release financial results for the second
quarter 2020, after the market close on Wednesday, July 29, 2020.
The company will host a conference call to discuss financial
results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 29,
2020. To participate on the conference call, please dial
(844) 850-0543 from the U.S. or (412) 317-5199 from outside the
U.S. In addition, following the completion of the call, a telephone
replay will be accessible until August 5,
2020 by dialing (877) 344-7529 from the U.S. or (412)
317-0088 from outside the U.S. and entering conference ID
#10145659. Those interested in listening to the conference
call live via the internet may do so by visiting the Webcasts page
of Viking's website at http://ir.vikingtherapeutics.com/webcasts.
An archive of the webcast will also be available on the Webcasts
page of the company's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel, orally available, first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders. Viking's research and development
activities leverage its expertise in metabolism to develop
innovative therapeutics designed to improve patients' lives.
The company's clinical programs include VK2809, a novel, orally
available, small molecule selective thyroid hormone receptor beta
agonist for the treatment of lipid and metabolic disorders, which
is currently being evaluated in a Phase 2b study for the
treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)
and fibrosis. In a Phase 2 trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company is also developing VK0214,
a novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of X-linked
adrenoleukodystrophy (X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for the treatment of type 2 diabetes as well as two
earlier-stage programs targeting metabolic diseases and
anemia. The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2020-on-july-29-2020-301098154.html
SOURCE Viking Therapeutics, Inc.